Compare Biogen Inc (BIIB) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Royal Bank of Canada — how do they compare? Biogen Inc trades at $191.19 (market cap $28.34B), while Royal Bank of Canada trades at $215.06 (market cap $294.58B). The key difference: Royal Bank of Canada is far larger — about 10.4× Biogen Inc's market cap, and Royal Bank of Canada pays a 2.38% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | RY | |
|---|---|---|
Market Cap | $28.34B | $294.58B |
Sector | Health | Financials |
52-Week High | $216.63 | $214.04 |
52-Week Low | $122.68 | $128.46 |
Enterprise Value | $30.62B | — |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Royal Bank of Canada (RY) trades at $210.69, down 0.19% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a P/E of 19.45, net income margin of 31.85%, and ROE of 17.17%. Recent Q2 2026 earnings of $2.84 per share exceeded expectations, and the company announced a dividend increase to $1.76 per share alongside a share repurchase program.
RY's outlook is supported by robust profitability and shareholder returns, but risks include a high P/B ratio of 3.21 and macroeconomic sensitivity. Analyst sentiment is mixed with a slight hold bias, yet the stock's technical strength and dividend growth present a compelling case for income-focused investors amid cautious market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
